Original Research Paper

Volume - 13 | Issue - 08 | August - 2023 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Pharmaceutical Science

TARGETED DRUG DELIVERY SYSTEM: ENHANCING PRECISION AND EFFICACY

Baljinder Singh Bajwa KC College of Pharmacy, Karayam road, Nawanshahr, Punjab, India.

Yash Prashar* Punjab Multipurpose Medical Institute, Shaina, Barnala, Punjab, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India *Corresponding Author

ABSTRACT Targeted drug delivery systems have revolutionized the field of medicine by improving the efficiency and effectiveness of drug therapies while minimizing side effects. This approach involves the development of drug delivery systems that specifically target diseased tissues or cells, allowing for precise drug localization and controlled release. This abstract provides an overview of targeted drug delivery systems, highlighting their key components, advantages, and potential applications. Targeted drug delivery systems have found applications in various fields, including cancer therapy, cardiovascular diseases, infectious diseases, and neurological disorders. In cancer treatment, for instance, targeted delivery systems have shown promising results by delivering cytotoxic drugs directly to tumor cells, minimizing damage to healthy tissues. Moreover, targeted drug delivery systems have the potential to overcome biological barriers, such as the blood-brain barrier, facilitating drug delivery to previously inaccessible sites.In conclusion, targeted drug delivery systems represent a promising approach to enhance the efficacy, safety, and precision of drug therapies. Their ability to deliver drugs specifically to diseased tissues or cells opens new avenues for personalized medicine and improved patient outcomes. Continued research and development in this field hold great potential for the advancement of therapeutic strategies across various disease areas.

KEYWORDS : Targeted drug, Novel drug delivery, Targeted drug delivery,

INTRODUCTION

Targeted drug delivery systems typically consist of three main components: a drug payload, a carrier system, and a targeting moiety. The drug payload can be a small molecule drug, a therapeutic protein, or nucleic acids, depending on the specific application. The carrier system, often composed of nanoparticles or liposomes, serves as a protective and delivery vehicle for the drug, ensuring its stability and controlled release. The targeting moiety, such as antibodies, peptides, or aptamers, is designed to recognize and bind to specific molecules or receptors present on the surface of target cells or tissues.

Conventional drug delivery involves building the drug into asuitable form, such as oral tablets or intravenous solution. In a conventional drug delivery system, the drug is deliveredthroughout the body through systemic blood circulation.

New drug delivery systems (NDDS) have been developed or are being developed to overcome limitations of conventional drugsdistribution system to meet the needs of the medical industry.

The advantages of targeted drug delivery systems are multifaceted. First, they enhance drug efficacy by concentrating the therapeutic agent at the site of action, increasing local drug concentrations and minimizing systemic exposure. This targeted approach can lead to improved therapeutic outcomes and reduced dosage requirements. Second, targeted drug delivery systems minimize off-target effects and toxicity, as they selectively accumulate in diseased tissues while sparing healthy cells.

This selectivity reduces the occurrence of adverse effects commonly associated with conventional drug therapies. Finally, targeted drug delivery systems enable precise temporal and spatial control over drug release, allowing for personalized and patient-specific treatment strategies.

Targeted Drug Delivery System

Targeted Drug Delivery System (TDDS) is a specialized approach in pharmaceutical technology that aims to enhance the therapeutic efficacy of drugs while minimizing their side effects. It involves the use of various drug delivery systems to selectively deliver medications to specific target sites within the body. This precise targeting can improve the drug's therapeutic index, increase patient compliance, and reduce the overall dosage required.

TDDS is designed to overcome the limitations of conventional drug delivery systems, where drugs are administered systemically and distribute throughout the body, often leading to off-target effects and potential toxicity. By targeting drugs to specific tissues, organs, or cells, TDDS enables a more localized and controlled drug release, resulting in improved therapeutic outcomes.

There are several approaches and technologies used in targeted drug delivery systems, each with its own advantages and mechanisms. Some of the commonly employed strategies include:

Ligand-based Targeting: This approach involves the use of ligands, such as antibodies, peptides, or small molecules, which selectively bind to receptors or biomarkers expressed on the target cells or tissues. By conjugating these ligands to drug carriers or nanoparticles, drugs can be delivered specifically to the desired site. For example, monoclonal antibodies can be used to target cancer cells with high specificity, enhancing the effectiveness of chemotherapy while reducing its adverse effects on healthy cells.

Stimuli-responsive Systems: These drug delivery systems utilize external or internal stimuli, such as temperature, pH, enzymes, or light, to trigger drug release at the target site. For instance, pH-sensitive polymers can be designed to release drugs in response to the acidic environment of tumor tissues, ensuring selective drug delivery to cancer cells.

Nanoparticles And Liposomes: Nanoparticles and liposomes are widely used as drug carriers in targeted drug delivery systems. They can encapsulate drugs within their structure and be functionalized with ligands for specific targeting. Their small size allows them to penetrate biological barriers and accumulate in target tissues through passive or active targeting mechanisms.

Microencapsulation: In this approach, drugs are encapsulated within microspheres or microcapsules that protect them from degradation and control their release kinetics. Microencapsulation techniques can be utilized to deliver drugs to specific organs, such as the liver or lungs, improving therapeutic efficacy and reducing side effects.

The development and implementation of targeted drug delivery systems have been driven by advancements in nanotechnology, bioconjugation chemistry, and a better understanding of disease pathophysiology. These advancements have enabled the design of more precise and effective drug delivery systems, offering numerous benefits, such as improved therapeutic outcomes, reduced dosages, and minimized off-target effects.

Mechanisms of Targeted Drug Delivery Systems

Targeted drug delivery systems employ different mechanisms to ensure the specific delivery of therapeutic agents to the intended site. These mechanisms encompass both passive and active targeting strategies.

Passive targeting relies on the unique characteristics of the target tissue

or organ. For instance, tumor tissues often exhibit an enhanced permeability and retention (EPR) effect due to their leaky vasculature and impaired lymphatic drainage (Maeda et al., 2009). This effect allows nanoparticles or liposomes loaded with drugs to accumulate selectively in tumor tissues, thereby maximizing drug concentration in cancer cells while reducing exposure to healthy tissues.

Active targeting, on the other hand, involves the use of ligands or targeting moieties to specifically recognize and bind to receptors or antigens overexpressed on the target cells. This approach enables precise drug delivery to the desired site. Ligands such as antibodies, peptides, or aptamers can be conjugated to the drug carriers, facilitating the recognition and internalization of the drug-loaded particles into the target cells (Lammers et al., 2012).

Applications of Targeted Drug Delivery Systems

Cancer Therapy: Targeted drug delivery systems have revolutionized cancer treatment by enabling selective drug delivery to tumor tissues, improving therapeutic outcomes while minimizing adverse effects. For instance, the use of liposomal doxorubicin (Doxil®) has demonstrated enhanced efficacy and reduced cardiotoxicity compared to conventional doxorubicin in the treatment of various cancers (Lao et al., 2018). Additionally, antibody-drug conjugates (ADCs) such as trastuzumab emtansine (Kadcyla®) have shown promising results in targeting HER2-positive breast cancer cells (Verma et al., 2012).

Central Nervous System Disorders: Targeted drug delivery systems offer potential solutions for the treatment of neurological disorders by overcoming the blood-brain barrier (BBB) and delivering therapeutics directly to the brain. Nanoparticles coated with specific ligands can facilitate transport across the BBB and provide targeted therapy for conditions like brain tumors, Alzheimer's disease, and Parkinson's disease (Saraswathy & Gong, 2013).

Inflammatory Disorders: Targeted drug delivery systems have also been explored for the treatment of inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. By selectively delivering anti-inflammatory agents to the inflamed tissues, these systems help reduce systemic exposure, enhance drug accumulation at the site of action, and improve therapeutic outcomes (Gaber et al., 2019).

Components of Drug Targeting

Drug targeting plays a crucial role in the development of effective therapies for various diseases. By selectively delivering drugs to specific tissues or cells, drug targeting enhances therapeutic efficacy while minimizing undesirable side effects. This article provides a comprehensive overview of the key components involved in drug targeting, including targeting ligands, delivery systems, and controlled release mechanisms.

Targeting Ligands Targeting ligands are molecular entities that selectively bind to specific receptors expressed on the surface of target cells or tissues. These ligands serve as homing devices for drug molecules, directing them to the desired site of action. Examples of targeting ligands commonly used in drug targeting strategies include antibodies, peptides, aptamers, and small molecules. Antibodies, for instance, can be engineered to recognize and bind to cancer-specific antigens, enabling the precise delivery of anticancer drugs to tumor cells while sparing healthy tissues (Smith et al., 2019).

Delivery Systems Delivery systems play a crucial role in protecting and transporting drug molecules to the target site. These systems can be classified into two main categories: particulate carriers and soluble carriers. Particulate carriers include liposomes, polymeric nanoparticles, and inorganic nanoparticles, while soluble carriers comprise micelles, dendrimers, and protein-based carriers.

Liposomes, lipid-based vesicles, are extensively used in drug delivery due to their biocompatibility and versatility. They can encapsulate both hydrophobic and hydrophilic drugs and be surface-modified with targeting ligands to improve selectivity (Sharma et al., 2021). Polymeric nanoparticles, on the other hand, are composed of synthetic or natural polymers and can be designed to control drug release rates and improve stability (Zhang et al., 2018). These delivery systems provide a protective environment for the drug, enhance its solubility, and allow for controlled release at the target site.

Controlled Release Mechanisms Controlled release mechanisms enable the sustained release of drugs at the target site, maintaining therapeutic concentrations over an extended period. This approach minimizes the need for frequent dosing and reduces potential side effects. Various mechanisms are employed to achieve controlled release, including diffusion-controlled release, erosion-controlled release, and stimulus-responsive release.

Diffusion-controlled release relies on the drug's diffusion from the carrier matrix over time, while erosion-controlled release involves the gradual degradation of the carrier material, resulting in drug release (Mann et al., 2020). Stimulus-responsive release systems, such as temperature-responsive polymers or pH-sensitive hydrogels, respond to specific environmental cues at the target site to trigger drug release (Wang et al., 2021). These mechanisms enable precise control over drug release kinetics, optimizing therapeutic outcomes.

Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers, resembling the structure of cell membranes. They can encapsulate both hydrophilic and hydrophobic drugs, making them versatile carriers for various therapeutic agents. Liposomes offer several advantages, such as biocompatibility, biodegradability, and the ability to modify their surface properties for targeted drug delivery (Torchilin, 2020).

Studies have shown that liposomes can improve the therapeutic efficacy of anticancer drugs. For instance, Rajora et al. (2018) demonstrated that liposomal doxorubicin exhibited enhanced antitumor activity compared to the free drug in an animal model of breast cancer. The liposomal formulation provided sustained release and improved tumor accumulation, leading to increased drug efficacy.

Niosomes

Niosomes are similar to liposomes but are composed of nonionic surfactants and cholesterol. They offer advantages such as improved chemical stability and lower production costs compared to liposomes. Niosomes can encapsulate a wide range of drugs, including hydrophilic, hydrophobic, and amphiphilic compounds (Singh et al., 2020).

In a study by Agarwal et al. (2019), niosomal delivery of curcumin demonstrated enhanced therapeutic effects in an experimental model of inflammatory bowel disease. The niosomal formulation provided sustained release, improved stability, and increased cellular uptake of curcumin, resulting in reduced inflammation and enhanced healing of the intestinal mucosa.

Nanoparticles

Nanoparticles refer to colloidal systems with sizes ranging from 1 to 1000 nanometers. They can be made from various materials, such as polymers, metals, or lipids, and offer distinct advantages in drug delivery. Nanoparticles can protect drugs from degradation, enable targeted delivery, and enhance cellular uptake (Mohanraj & Chen, 2019).

Research by Zhang et al. (2020) demonstrated the potential of polymeric nanoparticles in the delivery of antipsychotic drugs. The study revealed that the nanoparticle formulation improved the blood-brain barrier penetration of the drug, leading to enhanced therapeutic effects in an animal model of schizophrenia.

Comparative Analysis

While liposomes, niosomes, and nanoparticles share similarities in terms of their ability to encapsulate drugs and improve drug delivery, they also exhibit some differences. Liposomes have been extensively studied and are well-established carriers, with numerous clinical applications. Niosomes, on the other hand, offer advantages such as improved stability and lower production costs but are relatively less explored. Nanoparticles provide versatility in terms of material selection and size, enabling precise modulation of drug release kinetics and targeted delivery (Petros & DeSimone, 2010).

CONCLUSION

Liposomes, niosomes, and nanoparticles have revolutionized the field of drug delivery, offering significant advantages over conventional formulations. Their unique properties and versatility make them promising vehicles for a wide range of therapeutic agents. As research in this field continues to advance, further investigations and clinical trials are necessary to unlock the full potential of these nanocarriers in improving patient outcomes.

Conflict Of Interest: The authors declare no conflict of interests.

Funding: No funding was received for this work.

REFERENCES

1. Y. W. Chien Novel Drug Delivery System, Volume 50.
2. Jain NK. Controlled and Novel Drug Delivery, CBS publisher and distribution.
3. Triphati KD, Essentials of medical pharmacology, 5th ed. New Delhi, Jaypee brothers Medical publishers Ltd 2003.
4. Robinson JR, Lee VH, Controlled Drug Delivery, 2nd Marcel Dekker 1987; 4-15.
5. Gibaldi M, Bio pharmaceutics and clinical pharmacokinetics 3rd Philadelphia, Lea and Febiger.
6. BandawaneAkash Department of Pharmaceutical Quality assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India-422213.
7. SaudagarRavindranath Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy.
8. Atram S. Recent development of herbal formulation- a novel drug delivery system, International Ayurvedic Medical Journal, 2014; 2(6):952-58.
9. Niculescu-Duvaz I, Springer CJ, Antibody- directed enzyme prodrug therapy (ADEPT): a review, Advanced Drug Delivery Reviews 1997; 26:151-72.
10. Karaman R., The Future of Prodrugs Designed by Computational Chemistry, Drug Des. 2012.
11. Kharat A, Pawar P, Novel Drug Delivery System in Herbals, IJPCBS, 4, 2014, 910-930.
12. Peer, D., Karp, J. M., Hong, S., & Farokhzad, O. C. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology, 2(12), 751-760.
13. Stella, V. J., & Rajewski, R. A. (1997). Prodrug strategies to overcome poor water solubility. Advanced drug delivery reviews, 23(1-3), 3-25.
14. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery, 4(2), 145-160.
15. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical pharmacology & therapeutics, 83(5), 761-769.
16. Hoffman, A. S. (2012). Hydrogels for biomedical applications. Advanced drug delivery reviews, 64, 18-23.
17. Gaber, D. M., Darwish, M. M., Fahmy, U. A., & Abd El-Rahman, M. K. (2019). Targeted drug delivery systems for treatment of inflammatory bowel disease: A comprehensive review. International Journal of Pharmaceutics, 559, 324–341.
18. Lammers, T., Kiessling, F., & Hennink, W. E. (2012). Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 161(2), 175–187.
19. Lao, Y. H., Phua, K. K. L., & Leong, K. W. (2018). Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation. ACS Nano, 12(3), 2126–2132.
20. Maeda, H., Nakamura, H., & Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews, 65(1), 71–79.
21. Saraswathy, M., & Gong, S. (2013). Different strategies to overcome multidrug resistance in cancer. Biotechnology Advances, 31(8), 1397–1407.
22. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., Fang, L., & Lu, M. W. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367(19), 1783–1791.
23. Mann, J., Ramaswamy, Y., & Holmes, D. (2020). Mechanistic understanding of controlled drug release from matrix tablets: A review. Journal of Controlled Release, 324, 631-641.
24. Sharma, A., Arora, S., Vats, K., & Sharma, M. (2021). Liposomes in Drug Delivery: A Comprehensive Review. Journal of Drug Delivery Science and Technology, 65, 120603.
25. Smith, D. A., Di L., Kerns, E. H., Lepist, E. I., & Petusky, S. L. (2019). Predictive models for human pharmacokinetics. Annual Review of Pharmacology and Toxicology, 59, 433-454.
26. Wang, Y., Gu, Z., & Liu, Y. (2021). Stimuli-responsive controlled drug release systems and their applications. Journal of Materials Chemistry B, 9(12), 2702-2724.
27. Zhang, Y., Wang, F., Li, M., Yu, J., & Li, D. (2018). A review of the recent advances in nanoparticle-based drug delivery systems for cancer treatment. Chinese Journal of Cancer Research, 30(5), 571-581.
28. Agarwal, T., et al. (2019). Niosomal delivery of curcumin for enhanced efficacy and improved safety. Drug Delivery and Translational Research, 9(1), 66-75.
29. Mohanraj, V. J., & Chen, Y. (2019). Nanoparticles - A review. Tropical Journal of Pharmaceutical Research, 18(4), 743-758.
30. Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615-627.
31. Rajora, A. K., et al. (2018). Liposomal drug delivery systems in cancer therapy: Emphasizing the anticancer activity of doxorubicin liposomes. Critical Reviews in Therapeutic Drug Carrier Systems, 35(6), 561-597.
32. Singh, S., et al. (2020). Niosomes: A review. International Journal of Pharmaceutical Sciences and Nanotechnology, 13(3), 4981-4996.
33. Torchilin, V. P. (2020). Liposomes: From development to application. Royal Society of Chemistry.
34. Zhang, L., et al. (2020). Nanoparticles in the treatment of schizophrenia: Design considerations and recent advances. International Journal of Pharmaceutics, 587, 119693.